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Abstract
Coenzyme Q10 (CoQ10) is a potent lipophilic antioxidant in cell membranes and a carrier of electrons in the mitochondrial
respiratory chain. We previously characterized the effects of varying severities of CoQ10 deficiency on ROS production and
mitochondrial bioenergetics in cells harboring genetic defects of CoQ10 biosynthesis. We observed a unimodal distribution
of ROS production with CoQ10 deficiency: cells with ,20% of CoQ10 and 50–70% of CoQ10 did not generate excess ROS
while cells with 30–45% of CoQ10 showed increased ROS production and lipid peroxidation. Because our previous studies
were limited to a small number of mutant cell lines with heterogeneous molecular defects, here, we treated 5 control and 2
mildly CoQ10 deficient fibroblasts with varying doses of 4-nitrobenzoate (4-NB), an analog of 4-hydroxybenzoate (4-HB) and
inhibitor of 4-para-hydroxybenzoate:polyprenyl transferase (COQ2) to induce a range of CoQ10 deficiencies. Our results
support the concept that the degree of CoQ10 deficiency in cells dictates the extent of ATP synthesis defects and ROS
production and that 40–50% residual CoQ10 produces maximal oxidative stress and cell death.
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Introduction
Ubiquinone or coenzyme Q (CoQ) is a lipophilic molecule
present in virtually all cell membranes. Essential for multiple
metabolic processes, CoQ is required for antioxidant defenses and
electron transport from complex I and II to complex III in the
mitochondrial respiratory chain [1–3]. CoQ is synthesized within
mitochondria and is composed of a benzoquinone ring and a
polyprenyl side chain. The length of the isoprenoid in ubiquinone
varies among species; the predominant form in human is
composed of 10 isoprenyl units and is designated CoQ10. Current
knowledge about CoQ biosynthetic pathway in eukaryotes is
mainly derived from studies of S. cerevisiae [4,5]. At least 10
complementation groups of Q mutant yeast have been identified
[6–8]. Whereas the quinone ring is derived from tyrosine or
phenylalanine, the isoprenoid side chain is generated by addition
of isopentenyl diphosphate molecules, derived from the mevalo-
nate pathway, to farnesyl diphosphate in multiple steps catalyzed
by polyprenyl diphosphate synthase (in human, a heterotetramer
of two protein subunits, PDSS1 and PDSS2) [9]. Decaprenyl
diphosphate and para-hydroxybenzoate (PHB) are condensed in a
reaction catalyzed by 4-hydroxybenzoate:polyprenyl transferase or
COQ2, and the benzoate ring is then modified by at least six
enzymes, which catalyze methylation, decarboxylation, and
hydroxylation reactions to synthesize CoQ10 [4,5,10]. ADCK3 is
a protein kinase involved in CoQ biosynthesis and its yeast
homolog, Coq8p, is required for the formation or maintenance of
the multisubunit Q-biosynthetic complex and phosphorylation of
Coq3p, Coq5p, and Coq7p [11–16].
Although CoQ10 deficiency has been identified in more than
100 patients with a wide spectrum of phenotypes, the molecular
genetic bases have been identified in a minority of the patients and
the pathophysiological consequences of human CoQ10 deficiency
at the cellular level remain largely unknown [17–19].
In previous studies, we investigated the consequences of
varying degrees of CoQ10 deficiency on ROS production,
mitochondrial functions, and cell viability in skin fibroblasts
with CoQ10 deficiency due to different molecular defects
including mutations in COQ2 [20], PDSS2 [21–23], ADCK3
(CABC1)[ 1 2 ] ,a n dCOQ9 [24]. We reported that cultured
fibroblasts with severe CoQ10 deficiency (,20% of normal) have
marked bioenergetic defects without significant oxidative stress,
whereas intermediate CoQ10 deficiency (30–45% of normal)
causes moderate bioenergetic defects but marked increases in
ROS production, lipid oxidation, and cell death [2,3]. Not
surprisingly, cells with mild CoQ10 deficiency (.60% of normal)
did not show increased ROS production or oxidative damage.
However, because we compared cultured fibroblasts with
diverse molecular genetic defects, factors other than CoQ10
deficiency may have contributed to their differing in vitro
phenotype. Therefore, to assess the role of CoQ10 level on
mitochondrial bioenergetics impairment, oxidative stress, and
cell death in a uniform genetic background, we treated multiple
cell lines with increasing dosages of 4-nitrobenzoate, which
inhibits 4-hydroxybenzoate:polyprenyltransferase (COQ2) lead-
ing to dose-dependent decreases of CoQ in mammalian cells
without directly inducing oxidative stress or mitochondrial
respiration impairment [25].
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Cell culture
Mitochondrial bioenergetic and oxidative stress experiments
were performed in 5 control skin fibroblasts cell lines with normal
CoQ10 levels and in 2 skin fibroblasts cell lines with ADCK3
mutations, P1 (p.Y514C and p.T584del) and P2 (homozygous
p.Q167LfxX36), previously demonstrated to have defects of
ubiquinone biosynthesis, measured by incorporation of radiola-
beled parahydroxybenzoate (
14C-PHB) (450 Ci/mol) [2,20].
Cells were grown in Dulbecco’s minimum essential medium
(DMEM) supplemented with 10% fetal bovine serum (FBS), 5 ml
MEM vitamins, 5 ml MEM non-essential amino acids, 1 ml
fungizone, and 5 ml penicillin-streptomycin until 50% confluent.
Experiments were performed after 6 days of incubation in
RPMI 1640 glucose-free medium with 10% regular FBS, 25 mM
HEPES, 1.5 mM Glutamax, 25 mM galactose, 1 ml fungizone,
and 5 ml penicillin-streptomycin supplemented with one of the
following: 4 mM DMSO, 1 mM 4-NB, 2 mM 4-NB, 3 mM 4-NB,
or 4 mM 4-NB. To demonstrate that the effects of 4 mM 4-NB
were caused by CoQ10 deficiency rather than side effects of the
compound, control cell lines were supplemented also with 4-
NB+2 mM 4-HB and 4-NB+ 5 mM CoQ10 [25,26].
We performed experiments in galactose-medium because we
previously demonstrated that CoQ10 deficient fibroblasts do not
manifest increased oxidative stress and cell death or reduced
m i t o c h o n d r i a lf u n c t i o nw h e nc u l t u r e di ng l u c o s e - r i c hm e d i u m[ 3 ] .
ADCK3 mutant skin fibroblasts manifest mitochondrial bioenergetics
impairment and oxidative stress when cultured in galactose RPMI
1640 media with dialyzed FBS, but not in galactose RPMI media with
undialyzed FBS because glucose in FBS allows anerobic glycolysis to
maintain the cellular energy charge [2]. In contrast, the slow
metabolism of galactose to glucose-1-phosphate is insufficient for
glycolyticsynthesisofATP oxidative phosphorylationisimpaired [27].
Medium was changed at day 1, 3 and 5, and cells were collected
at day 7 [25]. 4-NB and 4-HB (Sigma-Aldrich, St. Louis MO,
USA) were dissolved in DMSO and stored at 220uC in 0.1 M
stock solutions. All other cell culture reagents were obtained from
Invitrogen (Invitrogen Corp., Eugene, OR, USA).
All cell lines at passage 7–10 were cultured at least 3 times,
therefore, each value in the results represents the mean of at least 3
measurements.
CoQ10 levels
CoQ10 in fibroblasts was extracted in hexane:ethanol mixture.
The lipid component of the extract was separated by high-
performance liquid chromatography (HPLC) on a reverse phase
SymmetryH C18 3.5 mm, 4.66150 mm column (Waters), using a
mobile phase consisting of methanol, ethanol, 2-propanol, acetic
acid (500:500:15:15) and 50 mM sodium acetate at a flow rate of
0.9 ml/min. The electrochemical detection system consisted of an
ESA Coulochem III with a guard cell (upstream of the injector) at
+900 mV, conditioning cell at 600 mV (downstream of the
column), followed by the analytical cell at +500 mV. CoQ10
concentration was estimated by comparison of the peak area with
those of standard solutions of known concentrations [26].
Adenine nucleotides levels
To determine levels of adenine nucleotides, cells were washed in
ice-cold phosphate-buffered saline (PBS) and then collected in ice-
cold 0.5 M perchloric acid using a scraper. After centrifugation at
3,000 g for 3 min at 4uC, pellets were suspended in 200 ml of ice-
cold 0.5 M perchloric acid, vortexed for 30 s, and centrifuged at
11,000 g for 10 min at 4uC. The pellets were stored at 280uC for
protein measurement. Adenine nucleotides in supernatants were
measured in an Alliance HPLC (Waters Corporation, Milford,
MA, USA) with an Alltima C18-NUC HPLC reverse-phase
column (Alltech Associates, Deerfield, IL, USA) [3]. Adenine
nucleotide levels were expressed in nmol/mg protein [26].
Mitochondrial membrane potential
To estimate mitochondrial membrane potential, control and
mutant cells were exposed to tetramethylrhodamine ethyl ester
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USA). Approximately 1610
6 cells were trypsinized, incubated
with TMRE for 20 min at 37uC, washed twice with PBS, re-
suspended in 500 ml of PBS and kept in ice.
Cytofluorometric analysis of stained cells was performed on a
FACSCalibur. Data were acquired using Cell Pro Quest and
analyzed using Flowjo software (Becton Dickinson, NJ, USA) [2].
Oxidative stress analyses
To estimate production of ROS, control and mutant cells were
exposed to MitoSOX Red, a fluorochrome specific for anion
superoxide produced in the inner mitochondrial compartment
(Molecular Probes, Invitrogen Corp., Eugene, OR, USA).
Approximately 1610
6 cells were trypsinized, incubated with
MitoSox for 20 min at 37uC, washed twice with PBS and
resuspended in 500 ml of PBS. Cytofluorometric analysis was
performed on a FACSCalibur. Data were acquired using Cell Pro
Quest and analyzed using Flowjo software (Becton Dickinson, NJ,
USA) [3].
To assess oxidative damage, we assessed lipid peroxidation
(LPO) after 4 mM 4-NB supplementation. For LPO measure-
ments, confluent cells were collected in PBS from 15 cm plates
Figure 3. CoQ10 levels in control skin fibroblasts (n=5) after treatment with DMSO, 4 mM 4-NB alone, or 4 mM 4-NB+5 mM CoQ10.
The values are nmol/mg-protein (***P,0.001).
doi:10.1371/journal.pone.0030606.g003
Figure 2. CoQ10 levels in control skin fibroblasts (n=5) after treatment with DMSO, 4 mM 4-NB alone, or 4 mM 4-NB+2 mM 4-HB.
The values are nmol/mg-protein (***P,0.001).
doi:10.1371/journal.pone.0030606.g002
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suspended in 20 mM Tris–HCl buffer, pH 7.4, containing 5 mM
butylated hydroxytoluene, and sonicated to lyse the cell. To remove
large particles,the sampleswere centrifuged at3,000 gfor10 minat
4uC. Aliquots of the supernatants were either stored at 280uC for
total protein determination or used for LPO. Bioxytech LPO-568
assay kit was used to determine both malondialdehyde (MDA) and
4-hydroxyalkenals (4HE) (Oxis International, Foster City, CA,
USA). Concentrations of LPO were normalized per mg protein [3].
Cell death studies
Cellviability wasmonitored bytrypan blue exclusion.Numbers of
livinganddeadcellsweredeterminedusingtheCountessAutomated
Cell Counter (Invitrogen). Healthy nuclei from viable cells appeared
round and phase bright, whereas nuclei from dead or dying cells
appeared blue and irregularly shaped. All cells were counted and
results were expressed as the ratio of living versus total cells.
Statistical analysis
Control data are expressed as the mean 6 standard deviation
(SD)of5 different normal fibroblast lineseachanalyzed intriplicate.
Patients’ data are expressed as the mean 6 SD of triplicates
experiments. Unpaired Student’s T test with Welch correction was
used. A p-value ,0.05 was considered to be significant.
Results
CoQ10 level
Baseline levels of CoQ10 were reduced in ADCK3 mutant P1
(63%) and P2 (51%) relative to control fibroblasts (n=5). Control
and P2 fibroblasts showed decreased CoQ10 levels after 4 mM 4-
NB supplementation and trends towards decreased levels after
1 mM, 2 mM, and 3 mM 4-NB treatment. In contrast, P1
fibroblasts showed a trend towards reduced CoQ10 levels after 1–
4 mM 4-NB supplementation (Fig. 1).
Figure 4. Adenine nucleotides levels in control (n=5), P1 and P2 skin fibroblasts after 4-NB treatment (ATP in panel A and ATP/ADP
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4-HB completely restored CoQ10 levels (Fig. 2) . Co-treatment of
control fibroblasts with 4 mM 4-NB and 5 mM CoQ10 signifi-
cantly increased levels of CoQ10 (Fig. 3).
Adenine nucleotide levels
ATP level was significantly decreased in controls and P2
fibroblasts after 1 mM, 2 mM, 3 mM, and 4 mM 4-NB
supplementation (Fig. 4A). P1 fibroblasts showed a trend
towards reduction in ATP levels after 1–4 mM 4-NB supple-
mentation (Fig. 4A). Control and P2 fibroblasts showed
significant decreases in ATP/ADP ratio after 4 mM of 4-NB
supplementation and trends towards decreased levels after
1 mM, 2 mM, and 3 mM 4-NB treatment (Fig. 4B). Co-
treatment of control fibroblasts with 4 mM 4-NB and 2 mM 4-
HB completely restored ATP level and ATP/ADP ratio (Fig. 5A
and B).
Mitochondrial membrane potential
With 1 mM, 2 mM, and 3 mM 4-NB treatment, TMRE
staining of control fibroblast was not significantly altered
indicating stable mitochondrial membrane potential (DYm), but
a trend towards increased TMRE staining was observed with
4 mM 4-NB (Fig. 6). In contrast, after 2 mM, 3 mM, and 4 mM
4-NB supplementation, P1 and P2 cells revealed increased TMRE
staining (Fig. 6). Co-treatment of control fibroblasts with 4 mM 4-
NB and 2 mM 4-HB did not significantly alter TMRE intensity
(Fig. 7).
Oxidative stress analyses
Control fibroblasts showed significantly increased MitoSox
staining after 3 mM and 4 mM 4-NB treatment while P1 and
P2 fibroblasts showed significantly increased MitoSox staining
after 2 mM, 3 mM, and 4 mM 4-NB treatment (Fig. 8A). Control
fibroblasts treated with 4 mM 4-NB and 2 mM 4-HB showed
Figure 5. Adenine nucleotides levels in control skin fibroblasts (n=5) after co-treatment with 4 mM 4-NB+2 mM 4-HB (ATP in panel
A and ATP/ADP in panel B). The values are nmol/mg-protein (** P,0.01 vs. controls; ***P,0.001).
doi:10.1371/journal.pone.0030606.g005
CoQ10 Deficient Fibroblasts
PLoS ONE | www.plosone.org 5 February 2012 | Volume 7 | Issue 2 | e30606significantly less MitoSox staining than cells treated with 4 mM 4-
NB only (Fig. 9A).
Lipid peroxidation (LPO) was slightly increased in controls, P1
and P2 fibroblasts after 4 mM of 4-NB treatment (Fig. 8B).
Control fibroblasts treated with 4 mM 4-NB and 2 mM 4-HB
showed significantly less LPO than cells treated with only 4 mM 4-
NB (Fig. 9B).
MitoSox staining of control fibroblasts treated with 4 mM 4-NB
and 5 mM CoQ10 was not significantly different than staining in
cells treated with 4 mM 4-NB only (Fig. 10).
Cell death studies
Control fibroblasts showed significantly decreased cell viability
after 3 mM 4-NB and 4 mM 4-NB while P1 and P2 cells showed
decreased cell viability after 1 mM, 2 mm, 3 mM and 4 mM 4-
NB treatments (Fig. 11).
Cell viability was normalized in control fibroblasts after co-
treatment with 4 mM of 4-NB and 2 mM 4-HB (Fig. 12), but not
after co-treatment with 4 mM 4-NB and 5 mM CoQ10 (Fig. 13).
Discussion
Although a growing number of patients with CoQ10 deficiency
due to a variety of mutations in CoQ10 biosynthetic genes has been
reported [18], the pathophysiology of this syndrome is not well
understood. Previous studies in human fibroblasts with decreased
levels of CoQ10 indicated that different mechanisms might be
involved. Studying cultured fibroblasts from two siblings with
infantile-onset CoQ10-deficiency of unknown genetic etiology,
Geromel and colleagues found mild respiratory chain defects
without evidence of increased superoxide anions, lipid peroxida-
tion, or apoptosis-mediated cell death [28]. We observed similar
abnormalities in fibroblasts carrying mutations in COQ9 and
PDSS2 [2,3].
In contrast, Lopez-Martin and colleagues showed that fibro-
blasts from a patient with a homozygous COQ2 mutation require
uridine to maintain cell growth and proposed that deficiency of
CoQ10 impaired pyrimidine biosynthesis due to dependence of
dihydro-orotate dehydrogenase on ubiquinol [29]. In the same
mutant COQ2 cell lines, as well as in other two cell lines with
CoQ10 deficiency and unknown molecular defects, evidence of
autophagy and oxidative stress has been observed [22]. More
recently the same group showed evidence of increase ROS
production and autophagy in a cellular model of secondary CoQ10
deficiency due to the m.3243A.G mutation [30]. Intriguingly,
ultrastructural evidence of autophagy has also been found in
kidney of mice with a homozygous mutation in Pdss2 [31]. Rapid
improvements with supplemental CoQ10 or the antixoxidant
probucol suggest that autophagy might be triggered by oxidative
stress [32,33].
Our previous studies of cells lines harboring COQ2 mutations
have indicated that CoQ10 level correlates with the production of
ROS, and that oxidative stress plays an important role in the
demise of COQ2 mutant fibroblasts by activating cell-death related
pathways, which are averted by antioxidant supplementation
[3,26]. Based on these observations, we hypothesized that the
degree of CoQ10 deficiency in fibroblasts correlates with increased
ROS production and cell death, independently of the primary
molecular defect. In several mammalian cell lines other than
human skin fibroblasts, 4-NB has been shown to decrease CoQ
levels without any apparent direct toxic effects, in particular
without inducing oxidative stress [25].
Here, we showed in control skin fibroblasts that pharmacolog-
ical inhibition of COQ2 by 4-NB, leading to 40–50% residual
CoQ10, is associated with increased oxidative stress and reduced
viability, together with moderately decreased ATP levels and
ATP/ADP ratio, similar to our observations in 3 different cell lines
carrying mutations in COQ2.
Moreover, P1 and P2 ADCK3 mutant cells, which have 51–63%
residual CoQ10, do not show signs of oxidative stress at baseline,
but showed significant increases in ROS (indicated by MitoSox
staining) when they reached 40–50% residual CoQ10 levels, which
occurs, not surprisingly, after lower doses (2–4 mM) of 4-NB than
in control cell lines (4 mM 4NB). Intriguingly, wild-type control
and ADCK3 mutant cells reacted differently to 4-NB treatment. In
control skin fibroblasts, we observed that only after maximum
(4 mM) 4-NB treatment, CoQ10 content decreased significantly
with proportional reductions in ATP level, whereas ROS
production and trypan blue staining (indicating cell death)
increased significantly after only 3 mM 4-NB. In cells with ADCK3
mutations and decreased ubiquinone at baseline, 4-NB rapidly
induced further reductions in CoQ10 levels, which plateaued at
40% of normal. Decreased CoQ10 concentration was associated
with increased MitoSox and TMRE (indicating increased
mitochondrial membrane potential) staining, and with slightly
reduced cell viability while ATP levels were only mildly decreased.
ATP/ADP ratio decreased starting from 1 mM 4-NB in both
controls and mutant cells. Unexpectedly, we were unable to
Figure 6. Assessment of mitochondrial membrane potential
with TMRE in control (n=5), P1 and P2 skin fibroblasts after 4-
NB treatment. The values are expressed as percentage of controls, P1
and P2 after 4 mM DMSO treatment. (* P,0.05 vs. controls;***P,0.001
vs. controls).
doi:10.1371/journal.pone.0030606.g006
Figure 7. Assessment of mitochondrial membrane potential by
TMRE in control skin fibroblasts (n=5) after co-treatment with
4 mM 4-NB+2 mM 4-HB. The values are expressed as percentage of
the control skin fibroblasts after 4 mM DMSO.
doi:10.1371/journal.pone.0030606.g007
CoQ10 Deficient Fibroblasts
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P2 cells, which had baseline CoQ10 deficiency. A pilot experiment
of a control cell line treated with 8 mM 4-NB produced massive
and irreversible cell death (data not shown), thus, higher doses of
the compound could not be used to further decrease CoQ
biosynthesis. The effects of the treatment were less prominent but
were observed more rapidly in mutant cell lines relative to controls
In support of variable response of cell lines to 4-NB are published
observations that a human hepatocyte cell line (C3A cells) were
less responsive to 4-NB-mediated decreases in CoQ as compared
to rodent cell lines [25].
On one hand, CoQ10 deficiency appears to be deleterious in 4-
NB treated fibroblasts because rescue by co-treatment of cells with
4-HB and 4-NB normalized CoQ10 levels, bioenergic defects, and
oxidative stress. On the other hand, the compound may have toxic
effects in addition to inhibition of CoQ biosynthesis because
CoQ10 co-treatment did not rescue 4-NB effects and because of a
floor-effect of 4-NB, which did not decrease CoQ10 level below
40% of normal. Failure of CoQ10 supplementation to rescue 4-NB
toxicity is unlikely be due to inadequate penetration ubiquinone
into mitochondria because we previously observed that incubation
of ubiquinone-deficient fibroblasts with 5 mM CoQ10 for 1 week
increases ATP levels and ATP/ADP ratios significantly, indicating
normalization of the bioenergetic status and mitochondrial
functions [2,3].
We also reported that in both control and mutant cells,
mitochondrial membrane potential (DYm) was not reduced by low
CoQ10 content, but rather DYm appeared to increase propor-
tionally with increased ROS production and with decreased ATP
levels and ATP/ADP ratios, supporting the hypothesis that early
mitochondrial hyperpolarization might trigger mitochondrial
ROS formation [2]. It is possible that the mitochondrial
membrane potential is enhanced by the F(1)F(0) ATPase operating
in ‘reverse’ mode, as suggested by other in vitro models of
mitochondrial respiratory chain defects [34,35].
Thus, our work in human skin fibroblasts with pharmacolog-
ically induced defects of ubiquinone biosynthesis have confirmed
that increased ROS production contributes to the pathomecha-
nism of CoQ10 deficiency associated with inhibition of COQ2 and
that partial CoQ10 deficiency (40–50% residual) is associated with
Figure 8. Quantitation of MitoSox staining by flow cytometry (panel A) and oxidation of lipids (panel B) in control (n=5), P1 and P2
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(n=5) after co-treatment with 4 mM 4-NB+2 mM 4-HB. The values are expressed as percentage of the control skin fibroblasts after 4 mM
DMSO (** P,0.01).
doi:10.1371/journal.pone.0030606.g009
Figure 11. Trypan blue staining in control (n=5), P1 and P2
skin fibroblasts after 4-NB treatment. The values are expressed as
percentage of controls, P1 and P2 after 4 mM DMSO treatment. (*
P,0.05 vs. controls; ** P,0.01 vs. controls).
doi:10.1371/journal.pone.0030606.g011
Figure 10. Quantitation of MitoSox staining by flow cytometry
in control skin fibroblasts (n=5) after co-treatment with 4 mM
4-NB+5 mM CoQ10. The values are expressed as percentage of the
control skin fibroblasts after 4 mM DMSO (** P,0.01).
doi:10.1371/journal.pone.0030606.g010
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compared to CoQ10 defiency that is mild (.50% of normal) or
severe (,30% of normal) [2,3].
Our observations of deleterious oxidative stress in ubiquinone-
deficient human fibroblasts are supported by studies of other in
vitro and in vivo models of CoQ deficiency. ROS production was
enhanced in the coq10 and coq2 mutant S. cerevisiae [36,37] while
coq7 and coq2 mutant S. pombe displayed hypersensitivity to
hydrogen peroxide and a requirement for antioxidants for growth
on minimal medium indicating a key pathogenic role of oxidative
stress in yeast models of CoQ deficiency [38,39]. RNAi of coq-
1,coq-2, and coq-3 in C. elegans GABA neurons led to activation of
cell death pathway featuring elements of apoptosis and necrosis
[40], while, in C. elegans low CoQ levels causing respiratory
chain defects was associated with low ROS production and life
span extension [41]. Apoptosis was also observed in embryos of
embryonically lethal coq7 defective mice [42]; and intracellular
superoxide was significantly elevated in HL-60 cells treated with p-
aminobenzoate, an inhibitor of COQ2 [43]. Furthermore, as
noted above, the rapid improvement of Pdss2 mutant mice with
CoQ10 or probucol supplementation support the hypothesized role
of increased ROS production in the pathogenesis of CoQ
deficiency.
Our findings provide insights into the pathomechanisms
underlying primary CoQ deficiency by demonstrating that the
degree of bioenergetic defect and ROS production are related to
the level of ubiquinone. Thus, depending on the severity of CoQ10
deficiency, biochemical targets for therapy may vary and may be
relevant to other mitochondrial respiratory chain disorders.
Moreover, the results may be germane to the pathogenesis and
therapies of other neurodegenerative diseases with mitochondrial
dysfunction.
Figure 12. Quantitation of cell viability by trypan blue staining in control skin fibroblasts (n=5) after co-treatment with 4 mM 4-
NB+2 mM 4-HB. The values are expressed as percentage of the control skin fibroblasts after 4 mM DMSO.
doi:10.1371/journal.pone.0030606.g012
Figure 13. Trypan blue staining in control skin fibroblasts (n=5) after co-treatment with 4 mM 4-NB+5 mM CoQ10. The values are
expressed as percentage of the control skin fibroblasts after 4 mM DMSO. (* P,0.05 vs. controls; ** P,0.01 vs. controls).
doi:10.1371/journal.pone.0030606.g013
CoQ10 Deficient Fibroblasts
PLoS ONE | www.plosone.org 9 February 2012 | Volume 7 | Issue 2 | e30606Acknowledgments
The authors thank Drs. Meriem Tazir, Clotilde Lagier-Tourenne, and
Michel Koenig for providing skin fibroblast from patient 2; Dr. David
Lynch for referring patient 1; and Dr. Luis Carlos Lopez for reviewing the
manuscript.
Author Contributions
Conceived and designed the experiments: CMQ MH. Performed the
experiments: CMQ AN ST. Analyzed the data: CMQ AN MH.
Contributed reagents/materials/analysis tools: CMQ ST AN MH. Wrote
the paper: CMQ AN MH.
References
1. Bentinger M, Tekle M, Dallner G (2010) Coenzyme Q–biosynthesis and
functions. Biochem Biophys Res Commun 396: 74–79.
2. Quinzii CM, Lopez LC, Gilkerson RW, Dorado B, Coku J, et al. (2010)
Reactive oxygen species, oxidative stress, and cell death correlate with level of
CoQ10 deficiency. FASEB J 24: 3733–3743.
3. Quinzii CM, Lopez LC, Von-Moltke J, Naini A, Krishna S, et al. (2008)
Respiratory chain dysfunction and oxidative stress correlate with severity of
primary CoQ10 deficiency. FASEB J 22: 1874–1885.
4. Tran UC, Clarke CF (2007) Endogenous synthesis of coenzyme Q in eukaryotes.
Mitochondrion 7 Suppl: S62–71.
5. Kawamukai M (2009) Biosynthesis and bioproduction of coenzyme Q10 by
yeasts and other organisms. Biotechnol Appl Biochem 53: 217–226.
6. Barros MH, Johnson A, Gin P, Marbois BN, Clarke CF, et al. (2005) The
Saccharomyces cerevisiae COQ10 gene encodes a START domain protein
required for function of coenzyme Q in respiration. J Biol Chem 280:
42627–42635.
7. Johnson A, Gin P, Marbois BN, Hsieh EJ, Barros MH, et al. (2005) COQ9, a
new gene required for the biosynthesis of coenzyme Q in Saccharomyces
cerevisiae. J Biol Chem 280: 397–404.
8. Tzagoloff A, Dieckmann CL (1990) PET genes of Saccharomyces cerevisiae.
Microbiol Rev 54: 211–225.
9. Saiki R, Nagata T, Kainou T, Matsuda H, Kawamukai M (2005)
Characterization of solanesyl and decaprenyl diphosphate synthases in mice
and humans. FEBS J 272: 5606–5622.
10. Gin P, Hsu AY, Rothman SC, Jonassen T, Lee PT, et al. (2003) The
Saccharomyces cerevisiae COQ6 gene encodes a mitochondrial flavin-
dependent monooxygenase required for coenzyme Q biosynthesis. J Biol Chem
278: 25308–25316.
11. Do TQ, Hsu AY, Jonassen T, Lee PT, Clarke CF (2001) A defect in coenzyme
Q biosynthesis is responsible for the respiratory deficiency in Saccharomyces
cerevisiae abc1 mutants. J Biol Chem 276: 18161–18168.
12. Lagier-Tourenne C, Tazir M, Lopez LC, Quinzii CM, Assoum M, et al. (2008)
ADCK3, an ancestral kinase, is mutated in a form of recessive ataxia associated
with coenzyme Q10 deficiency. Am J Hum Genet 82: 661–672.
13. Mollet J, Delahodde A, Serre V, Chretien D, Schlemmer D, et al. (2008)
CABC1 gene mutations cause ubiquinone deficiency with cerebellar ataxia and
seizures. Am J Hum Genet 82: 623–630.
14. Tauche A, Krause-Buchholz U, Rodel G (2008) Ubiquinone biosynthesis in
Saccharomyces cerevisiae: the molecular organization of O-methylase Coq3p
depends on Abc1p/Coq8p. FEMS Yeast Res 8: 1263–1275.
15. Xie LX, Hsieh EJ, Watanabe S, Allan CM, Chen JY, et al. (2011) Expression of
the human atypical kinase ADCK3 rescues coenzyme Q biosynthesis and
phosphorylation of Coq polypeptides in yeast coq8 mutants. Biochim Biophys
Acta 1811: 348–360.
16. Padilla S, Tran UC, Jimenez-Hidalgo M, Lopez-Martin JM, Martin-
Montalvo A, et al. (2009) Hydroxylation of demethoxy-Q6 constitutes a control
point in yeast coenzyme Q6 biosynthesis. Cell Mol Life Sci 66: 173–186.
17. Emmanuele V, Quinzii C, Lopez LC, Berardo A, Naini A, et al. (2011) Clinical
and genetic heterogeneity of coenzyme Q10 deficiency; a study of 76 patients.
submitted.
18. Quinzii CM, Hirano M (2010) Coenzyme Q and mitochondrial disease. Dev
Disabil Res Rev 16: 183–188.
19. Rahman S, Clarke CF, Hirano M (2011) 176th ENMC International Workshop:
Diagnosis and treatment of coenzyme Q(10) deficiency. Neuromuscul Disord in
press.
20. Quinzii C, Naini A, Salviati L, Trevisson E, Navas P, et al. (2006) A Mutation in
Para-Hydroxybenzoate-Polyprenyl Transferase (COQ2) Causes Primary Coen-
zyme Q10 Deficiency. Am J Hum Genet 78: 345–349.
21. Lopez LC, Schuelke M, Quinzii CM, Kanki T, Rodenburg RJ, et al. (2006)
Leigh syndrome with nephropathy and CoQ10 deficiency due to decaprenyl
diphosphate synthase subunit 2 (PDSS2) mutations. Am J Hum Genet 79:
1125–1129.
22. Rodrigue ´z-Hernandez A, Cordero MD, Salviati L, Artuch R, Pineda M, et al.
(2009) Coenzyme Q deficiency triggers mitochondrial degradation by mito-
phagy. Autophagy 5: 19–32.
23. Diomedi-Camassei F, Di Giandomenico S, Santorelli FM, Caridi G, Piemonte F,
et al. (2007) COQ2 nephropathy: a newly described inherited mitochondrio-
pathy with primary renal involvement. J Am Soc Nephrol 18: 2773–2780.
24. Duncan AJ, Bitner-Glindzicz M, Meunier B, Costello H, Hargreaves IP, et al.
(2009) A nonsense mutation in COQ9 causes autosomal-recessive neonatal-onset
primary coenzyme Q10 deficiency: a potentially treatable form of mitochondrial
disease. Am J Hum Genet 84: 558–566.
25. Forsman U, Sjoberg M, Turunen M, Sindelar PJ (2010) 4-Nitrobenzoate inhibits
coenzyme Q biosynthesis in mammalian cell cultures. Nat Chem Biol 6:
515–517.
26. Lopez LC, Quinzii CM, Area E, Naini A, Rahman S, et al. (2010) Treatment of
CoQ(10) deficient fibroblasts with ubiquinone, CoQ analogs, and vitamin C:
time- and compound-dependent effects. PLoS One 5: e11897.
27. Robinson BH, Petrova-Benedict R, Buncic JR, Wallace DC (1992) Nonviability
of cells with oxidative defects in galactose medium: a screening test for affected
patient fibroblasts. Biochem Med Metab Biol 48: 122–126.
28. Geromel V, Kadhom N, Ceballos-Picot I, Chretien D, Munnich A, et al. (2001)
Human cultured skin fibroblasts survive profound inherited ubiquinone
depletion. Free Radic Res 35: 11–21.
29. Lopez-Martin JM, Salviati L, Trevisson E, Montini G, DiMauro S, et al. (2007)
Missense mutation of the COQ2 gene causes defects of bioenergetics and de
novo pyrimidine synthesis. Hum Mol Genet 16: 1091–1097.
30. Cota ´n D, Cordero MD, Garrido-Maraver J, Oropesa-Avila M, Rodriguez-
Hernandez A, et al. (2011) Secondary coenzyme Q10 deficiency triggers
mitochondria degradation by mitophagy in MELAS fibroblasts. FASEB J in
press.
31. Peng M, Jarett L, Meade R, Madaio MP, Hancock WW, et al. (2004) Mutant
prenyltransferase-like mitochondrial protein (PLMP) and mitochondrial abnor-
malities in kd/kd mice. Kidney Int 66: 20–28.
32. Falk MJ, Polyak E, Zhang Z, Peng M, King R, et al. (2011) Probucol ameliorates
renal and metabolic sequelae of primary CoQ deficiency in Pdss2 mutant mice.
EMBO Mol Med 3: 410–427.
33. Saiki R, Lunceford AL, Shi Y, Marbois B, King R, et al. (2008) Coenzyme Q10
supplementation rescues renal disease in Pdss2kd/kd mice with mutations in
prenyl diphosphate synthase subunit 2. Am J Physiol Renal Physiol 295:
F1535–1544.
34. McKenzie M, Liolitsa D, Akinshina N, Campanella M, Sisodiya S, et al. (2007)
Mitochondrial ND5 gene variation associated with encephalomyopathy and
mitochondrial ATP consumption. J Biol Chem 282: 36845–36852.
35. Abramov AY, Smulders-Srinivasan TK, Kirby DM, Acin-Perez R, Enriquez JA,
et al. (2010) Mechanism of neurodegeneration of neurons with mitochondrial
DNA mutations. Brain 133: 797–807.
36. Busso C, Bleicher L, Ferreira-Junior JR, Barros MH (2010) Site-directed
mutagenesis and structural modeling of Coq10p indicate the presence of a
tunnel for coenzyme Q6 binding. FEBS Lett 584: 1609–1614.
37. Davidson JF, Schiestl RH (2001) Mitochondrial respiratory electron carriers are
involved in oxidative stress during heat stress in Saccharomyces cerevisiae. Mol
Cell Biol 21: 8483–8489.
38. Miki R, Saiki R, Ozoe Y, Kawamukai M (2008) Comparison of a coq7 deletion
mutant with other respiration-defective mutants in fission yeast. FEBS J 275:
5309–5324.
39. Uchida N, Suzuki K, Saiki R, Kainou T, Tanaka K, et al. (2000) Phenotypes of
fission yeast defective in ubiquinone production due to disruption of the gene for
p-hydroxybenzoate polyprenyl diphosphate transferase. J Bacteriol 182:
6933–6939.
40. Earls LR, Hacker ML, Watson JD, Miller DM, 3rd (2010) Coenzyme Q protects
Caenorhabditis elegans GABA neurons from calcium-dependent degeneration.
Proc Natl Acad Sci U S A 107: 14460–14465.
41. Rodriguez-Aguilera JC, Gavilan A, Asencio C, Navas P (2005) The role of
ubiquinone in Caenorhabditis elegans longevity. Ageing Res Rev 4: 41–53.
42. Nakai D, Shimizu T, Nojiri H, Uchiyama S, Koike H, et al. (2004) coq7/clk-1
regulates mitochondrial respiration and the generation of reactive oxygen species
via coenzyme Q. Aging Cell 3: 273–281.
43. Gonza ´lez-Arago ´n D, Buro ´nMI,Lo ´pez-Lluch G, Herman MD, Go ´mez-Dia ´zC,
et al. (2005) Coenzyme Q and the regulation of intracellular steady-state levels of
superoxide in HL-60 cells. Biofactors 25: 31–41.
CoQ10 Deficient Fibroblasts
PLoS ONE | www.plosone.org 10 February 2012 | Volume 7 | Issue 2 | e30606